Investing Partners
INDUSTRY: Healthcare
SECTOR: Pharmaceutical industry
VERTICAL: Services to biotech companies
BUSINESS MODEL: RNA encapsulation and delivery technology for innovative RNA based therapies
GROWTH INITIATIVES: Licensing of RNA encapsulation and delivery technology to big/mid pharmas and biotech companies developing innovative drugs in RNA therapies
INVESTMENT DATE: 2021
LOCATION: France (Toulouse, 31)
RNAlead has developed a proprietary technology, derived from vectors, to encapsulate RNA of interest to be injected in patients to enable them to benefit from RNA treatment.
It is an alternative to LNP technology, with an independent proprietary IP, more effective (>30x), and safer, without genome insertion and low immunogenicity.
The field of application are all therapies leveraging RNA: gene therapy, genome edition, cell reprogramming, vaccination, immunotherapy